ARS Pharmaceuticals, Inc. SPRY Proceeds From Sale Of Short Term Investments

Proceeds From Sale Of Short Term Investments at other companies

Monolithic Power SystemsMPWR

$14.44M-89.8%

CSXCSX

$5M-92.5%

Southern CopperSCCO

$423.58M+75.4%

FedExFDX

$27.5M+189%

Advanced Micro DevicesAMD

$126M+282%

Electronic ArtsEA

$42M-87.2%

Other financials

Income statement

See full

Revenue$22.7M+184%

Operating income-$60.1M-61.8%

Net income-$60.6M-78.6%

EPS (diluted)-$0.61-74.3%

Balance sheet

See full

Cash & equivalents$24.3M-39.0%

Total debt$96.5M+132,122%

Total equity$61.3M-73.2%

Total assets$287.6M-12.1%

Cash flow

See full

Operating cash flow-$44.9M-10.3%

CapEx--100%

Free cash flow-$44.9M-10.1%

Valuation

See full

Market cap$796.41M-48.7%

Enterprise value$868.61M-42.6%

P/S8.1×-7.9×

Profitability

See full

Operating margin-204.5%—

Net margin-200%-219pp

FCF margin-177.1%-206pp

Returns & leverage

See full

Return on equity-136.4%-144pp

Debt / equity1.6×+1.6×

Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s proceeds from sale of short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s proceeds from sale of short term investments?: ARS Pharmaceuticals, Inc. (SPRY) reported proceeds from sale of short term investments of $42.5M in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s proceeds from sale of short term investments changed year-over-year?: ARS Pharmaceuticals, Inc.'s proceeds from sale of short term investments decreased by 33.1% year-over-year, from $63.5M to $42.5M.